Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapy

Am J Hematol. 2022 Feb 1;97(2):E47-E51. doi: 10.1002/ajh.26411. Epub 2021 Nov 24.

Authors

Relja Popovic¹, Fengjiao Dunbar¹, Charles Lu¹, Kenneth Robinson¹, Danjuma Quarless¹, Scott E Warder¹, Nabanita Mukherjee¹, John Pesko¹, Andrew J Souers¹, Jeffrey F Waring¹, Matthew S Davids², Eugen Tausch³, Stephan Stilgenbauer³, Jeremy A Ross¹, Joel D Leverson¹, Su Young Kim¹, Brenda J Chyla¹

Affiliations

¹ AbbVie Inc, North Chicago, Illinois, USA.
² Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
³ Internal Medicine III, Ulm University, Ulm, Germany.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use*
Apoptosis / drug effects*
Bridged Bicyclo Compounds, Heterocyclic / pharmacology
Bridged Bicyclo Compounds, Heterocyclic / therapeutic use*
Cell Line, Tumor
Drug Resistance, Neoplasm
Gene Expression Regulation, Leukemic / drug effects
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
Leukemia, Lymphocytic, Chronic, B-Cell / genetics
Mutation / drug effects
Sulfonamides / pharmacology
Sulfonamides / therapeutic use*

Substances

Antineoplastic Agents
Bridged Bicyclo Compounds, Heterocyclic
Sulfonamides
venetoclax